Are humanin and MOTS-c related?

Only by category. Both are mitochondrial-derived peptides, but they come from different genes, share no sequence, and act by different mechanisms.

Does MOTS-c have a receptor?

None has been established. Its characterised activity is intracellular rather than receptor-mediated at the cell surface.

Which is better studied?

Humanin has a longer literature by virtue of a fourteen-year head start, though MOTS-c has attracted rapid interest since 2015.

MOTS-c (Mitochondrial Peptide)

MOTS-c vs Humanin: How They Differ

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Humanin and MOTS-c are both encoded in mitochondrial DNA, but in different genes — humanin in the 16S rRNA gene, MOTS-c in the 12S. Humanin is 24 residues and acts through a cell-surface receptor complex, studied largely in neuroprotection. MOTS-c is 16 residues, acts on metabolism through AMPK, and has no established receptor.

Key facts

Humanin gene: 16S rRNA
MOTS-c gene: 12S rRNA
Humanin length: 24 residues
MOTS-c length: 16 residues
Humanin identified: 2001
MOTS-c identified: 2015
Humanin research focus: Neuroprotection, cytoprotection
MOTS-c research focus: Metabolism, AMPK signalling

Different genes, same genome

Both peptides are encoded within ribosomal RNA genes in the mitochondrial genome, but not the same one. Humanin's open reading frame sits inside the 16S rRNA gene; MOTS-c's sits inside the 12S. They are not variants of one another and share no sequence relationship — they are independent discoveries that happen to belong to the same structural category.

How they were found

Humanin came first, in 2001, identified from surviving neurons in an Alzheimer's disease brain — the question being why those particular cells persisted. MOTS-c came in 2015 from a deliberate search of the mitochondrial genome for further short open reading frames, informed by humanin's existence. The first was serendipitous; the second was systematic.

Research material referenced

MOTS-C 10mg — third-party HPLC tested

View — £24.99

Receptor biology

This is the sharpest difference. Humanin has an identified cell-surface receptor complex and behaves like a classical secreted ligand. MOTS-c has no established receptor. Its characterised action is intracellular, through the folate cycle and AMPK, and it translocates to the nucleus under stress. One acts from the outside in; the other appears to act from the inside.

Research emphasis

Humanin's literature is dominated by neuroprotection and cytoprotection, following from its discovery context. MOTS-c's is dominated by metabolism, insulin sensitivity, exercise physiology and ageing. The two bodies of work overlap in ageing biology but otherwise address different questions.

What they share

Both are encoded in mitochondrial DNA, both were missed for decades because their reading frames overlap annotated rRNA genes, both are studied in the context of ageing, and both have literature that is overwhelmingly preclinical. Neither is an approved medicine in any jurisdiction.

Quick reference

	MOTS-c	Humanin
Gene of origin	12S rRNA	16S rRNA
Length	16 residues	24 residues
Identified	2015	2001
Known receptor	None established	Cell-surface complex
Primary mechanism	Folate cycle → AICAR → AMPK	Receptor-mediated signalling
Research focus	Metabolism, exercise, ageing	Neuroprotection, cytoprotection

Extended research context

The MOTS-c (Mitochondrial Peptide) deep dive

Deep dive: why a peptide encoded in mitochondrial DNA is unusual

The human mitochondrial genome is 16,569 base pairs encoding 37 genes, and was considered fully characterised by the 1980s: thirteen respiratory-chain proteins, twenty-two transfer RNAs, two ribosomal RNAs. MOTS-c is encoded by a short open reading frame nested inside the 12S rRNA gene — sequence already annotated as doing something else, which is exactly why it went unnoticed. Humanin, found in 2001 inside the 16S rRNA gene, established that the genome held more than its annotation suggested; MOTS-c was found in 2015 by looking deliberately. The implication is that the mitochondrion encodes and releases signalling molecules of its own, rather than only executing instructions sent from the nucleus.

Deep dive: AMPK activation without touching AMPK

AMPK is normally activated when AMP and ADP bind its gamma subunit, making it a direct sensor of the AMP-to-ATP ratio. MOTS-c does not raise that ratio and does not bind the kinase. It inhibits the folate cycle, the one-carbon pathway feeding de novo purine biosynthesis, and the intermediate AICAR accumulates as a result. AICAR is an AMP mimetic — phosphorylated to ZMP, it binds the same regulatory site AMP occupies. So the peptide reaches a cytosolic energy sensor through one-carbon metabolism and a diffusible small molecule, which is a materially different architecture from a receptor-ligand interaction, and different again from metformin's inhibition of complex I.

Deep dive: reading a preclinical literature honestly

Roughly 250 indexed papers exist, and the overwhelming majority are cell and rodent studies. Where humans appear, the work is generally observational: measuring circulating concentrations and correlating them with age, fitness or metabolic state. The 2021 Nature Communications paper is the clearest example of the structure — the human arm measured MOTS-c before and after exercise, finding roughly a 12-fold rise in skeletal muscle against 1.6-fold in circulation, while the interventional work was done in mice. Two inferences the secondary literature routinely makes and the primary literature does not support: that a correlation between low concentrations and poor metabolic health establishes direction, and that a molecule which rises during exercise would reproduce exercise if administered.

Research applications

▸Study of mitochondrial-derived peptides and retrograde signalling
▸AMPK pathway research through non-canonical activation
▸One-carbon and folate-cycle metabolism models
▸Exercise physiology and mitochondrial bioenergetics research
▸Ageing biology and mitochondrial genome expression studies

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the primary degradation route (+16 Da per residue)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check mass spectrometry for +16 and +32 satellites before relying on a batch

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Reading exercise induction as proof that administration mimics exercise

Fix: The papers report that exercise raises MOTS-c. The reverse inference is not supported and is not claimed.

✗ Treating human observational data as interventional evidence

Fix: Human work measures endogenous concentrations; administration studies were conducted in mice.

✗ Assuming MOTS-c has a cell-surface receptor like humanin

Fix: No receptor is established. Its characterised activity is intracellular.

✗ Storing reconstituted material as though it were as stable as the powder

Fix: Solution-phase material is subject to hydrolysis and oxidation; the lyophilised form is far more stable.

✗ Overlooking WADA status in athlete-adjacent research

Fix: MOTS-c is on the prohibited list; this is relevant to any research context involving competitors.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Are humanin and MOTS-c related?: Only by category. Both are mitochondrial-derived peptides, but they come from different genes, share no sequence, and act by different mechanisms.
Does MOTS-c have a receptor?: None has been established. Its characterised activity is intracellular rather than receptor-mediated at the cell surface.
Which is better studied?: Humanin has a longer literature by virtue of a fourteen-year head start, though MOTS-c has attracted rapid interest since 2015.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MOTS-c (Mitochondrial Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum